Navigation Links
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
Date:6/9/2009

Anti-TNF Experienced Patients Demonstrated Improvement With Every-Four-Week Subcutaneous SIMPONI Despite Previous Medication or Reason for Discontinuation

COPENHAGEN, June 9 /PRNewswire/ -- A new analysis demonstrated that a greater proportion of patients with moderately to severely active rheumatoid arthritis (RA) who had prior treatment with anti-tumor necrosis factor (TNF)-alpha agents and received subcutaneous injections of SIMPONI(TM) (golimumab) once every four weeks experienced significant improvements in signs and symptoms through week 24, compared with patients receiving placebo. Patients continued to receive stable doses of methotrexate, sulfasalazine and/or hydroxychloroquine if receiving them at baseline. These data were presented at the 2009 European League Against Rheumatism (EULAR) Annual Congress.

Findings from the GOlimumab After Former anti-TNF Therapy Evaluated in RA (GO-AFTER) study, demonstrated that patients previously treated with adalimumab, etanercept or infliximab responded to and tolerated SIMPONI regardless of the type of prior anti-TNF therapy, as well as the number of prior therapies or reason for discontinuation. According to the study, 39 percent of patients receiving SIMPONI whose prior anti-TNF-alpha therapy had been discontinued due to a lack of efficacy achieved at least a 20 percent improvement in arthritis symptoms (ACR 20) at week 14, compared with 18 percent of patients receiving placebo (p<0.001). Thirty-four percent of patients receiving SIMPONI whose prior anti-TNF-alpha therapy had been discontinued for all other reasons achieved ACR 20, compared with 20 percent of patients receiving placebo (p=0.027).

"Golimumab has shown promise in the treatment of rheumatoid arthritis patients who have previously discontinued other anti-TNF-alpha therapies," said Josef S. Smolen, MD, Professor and Chairman, Departm
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
2. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
3. SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease
4. New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
5. New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
6. New Imaging Analysis Predicts Brain Tumor Survival
7. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
8. CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
9. SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease
10. CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals
11. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... EMERYVILLE, Calif. , Sept. 17, 2014 /PRNewswire/ ... newest data analytics solution that brings complete visibility ... minimize risks in an ever-evolving reimbursement landscape. Powered ... Integrity brings transparency to the critical point between ... operations impact revenue. The solution will improve revenue ...
(Date:9/17/2014)... MADISON, Tenn. , Sept. 17, 2014 ... be; these infections are not only uncomfortable, they,re often ... best-laid social plans. pH-D Feminine Health Support ( http://ph-defense.com ... vaginal health. It is an all-natural, homeopathic product. ... the most common symptoms of vaginal infection. In many ...
(Date:9/17/2014)... , Sept. 17, 2014  Aratana Therapeutics, Inc. ... company focused on licensing, developing and commercializing innovative ... pricing of its public offering of 4,500,000 shares of its ... of $9.25 per share. Aratana has granted the ... an additional 675,000 shares of its common stock. ...
Breaking Medicine Technology:MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3New Product from Vireo Systems: pH-D Feminine Health Support 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2
... DELAND, Fla., May 13 USHIFU, LLC, the clinical ... pleased,to announce conditional written approval pending minor changes to ... for the treatment of,recurrent prostate cancer with the Sonablate(R) ... Dr. Herbert Lepor, Chairman of Urology at NYU ...
... Products Expand Infection Prevention Business, DUBLIN, Ohio, ... products and services that improve the safety and,productivity ... the,acquisition of assets of privately held Enturia, Inc., ... ChloraPrep(R) brand name., ChloraPrep(R) brand products are ...
Cached Medicine Technology:FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer 2Cardinal Health Completes Enturia Acquisition 2
(Date:9/17/2014)... Asian Americans at higher risk of developing type 2 ... disease at lower body weights? One part of this ... low-fat Asian diets to current westernized diets, which may ... George King, M.D., Senior Vice President and Chief Scientific ... of the study. , A Joslin randomized clinical trial ...
(Date:9/17/2014)... The in vitro diagnostics (IVD) marketplace ... focusing on molecular diagnostics for conditions such as infectious ... The IVD market value is projected to be worth ... The major drivers of the market’s growth include the ... evidenced by the explosion for raid and minimally-invasive diagnostic ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, 2014 ... explain why antibiotic-resistant bacteria can thrive in a hospital setting. ... be the culprit. They can easily enter bacteria and move ... that makes bacteria drug-resistant, a new study finds. "The ... a class of antibiotic called carbapenems," said the study,s co-author, ...
(Date:9/17/2014)... Research has shown that most 18-month-olds learn an average ... little is known about how children process information to ... years. In a new study, a University of Missouri ... they age, and a limit exists as to how ... could help parents enhance their children,s vocabularies and assist ...
(Date:9/17/2014)... September 17, 2014 Celestix Networks, ... solutions, today announced that it will launch a ... 2014. This new offering will provide seamless Active ... Software-as-a-Service applications to enable secure single sign-on and ... of cloud computing, there has been a dramatic ...
Breaking Medicine News(10 mins):Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 2Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 3Health News:Babies learn words differently as they age, researcher finds 2Health News:Celestix Announces Availability of ADFS Bridge Appliance in October 2014 to Simplify the Configuration of Office 365 with Active Directory 2
... Benedict XVI’s intention of soliciting a report on the acceptability ... //in exceptional cases, such as, in the event of either ... life within the precincts of marriage. ,Experts have commended ... issue such as this, while also agreeing that such an ...
... on its last lap of seeking enrollment from drug companies, and ... with three major insurance players. ,United Health Group seems to ... endorsers and a financial agreement with them to support the company. ... Medicare. ,80 companies have been in the fray with ...
... mother’s heart disease rather than the father’s tend to pose ... history of coronary disease//. ,The results of the ... American Journal of Preventive Medicine. This could help to better ... coronary problems as well as show early signs of the ...
... getting known for its severe dearth of general practitioners, further ... in the throes of a severe GP crisis. ,The ... the current trend of Doctors, gravitating to specialist sectors, which ... GP sector lean and totally understaffed. ,Dr Catherine ...
... been accused of the murder of three family members whose ... court appearance. // ,The victims were Marc Richardson, ... and a funeral visitation has been planned for them today ... Toussaint Church in Sudbury. ,The girl's boyfriend, an ...
... The World Health Organization WHO has recently released its ... // The United Nations health agency found that ... they are adequately nurtured and they claimed that the ... ,The W.H.O. says it now has scientific evidence ...
Cached Medicine News:Health News:Risk of Heart Disease Greater from Mom than Dad 2Health News:An International Growth Standard For Childs Releases By WHO 2
... Digital Wide Field Lens combines ... high magnification. The enhanced double ... provide high resolution stereo views ... reflections. These unique features make ...
... Stereo Fundus Lens is specifically designed for ... retina. Its enhanced 3-D stereoscopic design enables ... detail, making it ideal for detecting changes ... serous detachments and other macular abnormalities. It ...
The Pan Retinal® 2.2 uniquely combines magnification nearly that of the 20D lens with a field of view approaching that of the 30D lens. Excellent for virtually every examination procedure, includ...
... Volks state-of-the-art 20D diagnostic/laser lens ... astigmatic aberrations and coma delivering ... 20 diopter lens on the market. ... maintains linear image magnification and perfect ...
Medicine Products: